Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Receivables: 2020-2024

  • Janux Therapeutics' Receivables was N/A to $12.1 million in Q2 2024 from the same period last year, while for Jun 2024 it was $17.8 million, marking a year-over-year change of. This contributed to the annual value of $8.0 million for FY2020, which is N/A change from last year.
  • Latest data reveals that Janux Therapeutics reported Receivables of $12.1 million as of Q2 2024, which was up 173.69% from $4.4 million recorded in Q1 2024.
  • Over the past 5 years, Janux Therapeutics' Receivables peaked at $12.1 million during Q2 2024, and registered a low of $400,000 during Q2 2021.
  • Over the past 3 years, Janux Therapeutics' median Receivables value was $2.6 million (recorded in 2023), while the average stood at $4.4 million.
  • Data for Janux Therapeutics' Receivables shows a peak YoY skyrocketed of 450.62% (in 2024) over the last 5 years.
  • Over the past 5 years, Janux Therapeutics' Receivables (Quarterly) stood at $8.0 million in 2020, then reached $400,000 in 2021, then reached $500,000 in 2022, then reached $800,000 in 2023, then soared by 450.62% to $12.1 million in 2024.
  • Its last three reported values are $12.1 million in Q2 2024, $4.4 million for Q1 2024, and $800,000 during Q1 2023.